REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01803828
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT01803828
-
- Other papers using this trial's data
- Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT01803828. Randomized; double masking; primary purpose treatment. Start 2014-05 (actual); primary completion 2019-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs
- Acronym
- RECOGITO
- Condition
- Diabetic Cardiomyopathy
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Roma La Sapienza
Record details
- Record id
cardio:ct-nct01803828- Content hash
65f75cd593ef411dde58314777863172eecdd72c0acfc585eeeca79f8cbe74f7